Signal active
Organization
Contact Information
Overview
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Tryptamine Therapeutics intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Tryp’s lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy.
About
Biotechnology
2019
1-10
Headquarters locations
Kelowna, British Columbia, Canada, North America
Social
Profile Resume
Tryptamine Therapeutics headquartered in North America, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $309.7M in funding across 20 round(s). With a team of 1-10 employees, Tryptamine Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Tryptamine Therapeutics, raised $4.2M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
5
0
0
$15.5M
Details
0
Tryptamine Therapeutics has raised a total of $15.5M in funding over 0 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|
Investors
Tryptamine Therapeutics is funded by 4 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Tryptamine Therapeutics | - | FUNDING ROUND - Tryptamine Therapeutics | 1.6M |
Marc Lustig | - | FUNDING ROUND - Marc Lustig | 1.6M |
Tryptamine Therapeutics | - | FUNDING ROUND - Tryptamine Therapeutics | 2.1M |
Jason Carroll | - | FUNDING ROUND - Jason Carroll | 2.1M |
Recent Activity
News
Sep 02, 2024
MarketScreener - Tryptamine Therapeutics Limited Announces Chief Financial Officer Changes
News
Jun 14, 2024
Global Legal Chronicle - Tryptamine Therapeutics Limited’s Acquisition and Backdoor Listing of Tryp Therapeutics
News
May 25, 2024
Yahoo Finance - Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024
News
May 25, 2024
Yahoo Finance - Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
News
May 17, 2024
Tipranks - Tryptamine Expands Psychedelic Treatment Trials - TipRanks.com
Funding Round
May 01, 2024
Tryptamine Therapeutics raised $4244596 on 2024-05-01 in Post-IPO Equity